#IgGenix will present new data on #AlphagalSyndrome (AGS) at #AAAAI2025 / WAO Joint Congress! These data enrich our understanding of AGS and may help lead to breakthrough therapies for people suffering from this complex condition. More info:

Exciting news! #TeamIgGenix will be attending the #AAAAI2025 Annual Meeting / WAO Joint Congress! Come join us as we showcase exciting new data for the treatment of alpha-gal syndrome, and share the latest updates in our mission to solve #allergies. #AllergyResearch

Struggling with a #PeanutAllergy? #ACCELERATEPeanut, a new study led by #TeamIgGenix, raises hope for those affected by peanut allergies— and possibly other food allergies as well—with a breakthrough solution. Check out this article for more info:

The #ACCELERATEPeanut study is exploring a novel mechanism of action to improve safety and expand options for patients. Here, Dr. Tong shares why this groundbreaking Phase 1 trial is an exciting step forward. Visit @NACEresearch Allergy Studies Directory:

#Winterallergies are often triggered by what’s inside—dust mites, pet dander, mold—rather than the cold outdoors. Learn more about the causes, symptoms, and how to manage them in this article from @AllergyAsthmaHQ:

Accidental allergen exposure can be life-threatening. The #ACCELERATEPeanut study explores new ways to protect patients—without using direct allergen exposure. Visit the @NACEresearch Allergy Studies Directory to learn more:

How does IGNX001 neutralize peanut allergens? In a Q&A with @GoHealio, CEO Dr. Jessica Grossman shares insights on the science behind our ACCELERATE Peanut study & its potential to transform #peanutallergy care. Read: #ACCELERATEPeanut @HealioAllergy

We’re thankful for the hard work that #TeamIgGenix and @NACEresearch partners have achieved this year. From launching the #ACCELERATEPeanut study to advancing allergy research, we couldn’t do it without you. Wishing everyone a happy and safe Thanksgiving!

Our #ACCELERATEPeanut study transforms harmful IgE antibodies into protective IgG4 antibodies, working to prevent severe allergic reactions before they happen. Watch Dr. Andrew Carr of St. Vincent's Hospital explain the importance of this therapy for all age groups.

Being part of Lilly Gateway Labs means working with biotech leaders to advance innovation in #allergy research. Together, we’re driving progress toward better therapies for allergic diseases.

An estimated 16.5 million U.S. adults have #atopicdermatitis, with 40% experiencing moderate to severe disease, according to @nationaleczema. At IgGenix, we’re committed to finding new solutions for #eczema - during #HealthySkinMonth and beyond.

Fall means #seasonalallergies for a quarter of U.S. adults. At IgGenix, we’re working to tackle environmental allergens through groundbreaking research, so people can enjoy the season without the sneezing! Learn more about our work:

Last month, IgGenix participated in #ASCIA2024, where we showcased our ongoing work on the #ACCELERATEPeanut study. We’re proud to be part of important conversations shaping the next generation of treatments for #allergies and IgE-mediated diseases.

30 - 40% of the world’s population suffers from one or more allergic conditions, according to @StanfordMed. Understanding these reactions is key to developing solutions that could improve millions of lives. Explore our work: #WorldAllergyAwarenessDay

We’re proud to announce the first patient has been dosed in our Phase 1 #ACCELERATEPeanut study! This marks a new chapter as we advance our IgE antibody platform, aiming for faster, more effective protection against severe allergic reactions.

Allergies affect about 27% of U.S. children, according to the @CDCgov, disrupting daily life and contributing to long-term health challenges. We're committed to advancing research to ease the burden of severe allergic reactions. #ChildrensHealthMonth

We’re at #BioJapan2024, connecting with biotech leaders about our #ACCELERATEPeanut study and allergy research. Excited to discuss IgGenix’s innovative approach to IgE-mediated diseases! @BioJapanExpo

Our #ACCELERATEPeanut Study uses IgE antibody technology to explore new approaches in allergy research. By transforming harmful IgE antibodies into blockers, we aim to prevent allergic reactions at the source. Explore our study at @NACEresearch:

#NationalEczemaWeek is a time to raise awareness about the challenges millions of Americans face living with #eczema. At IgGenix, we’re focused on researching and understanding the underlying causes of conditions like eczema to find new ways to address this ongoing struggle.

#WorldAtopicDermatitisDay is tomorrow. We're shining a light on the millions of people living with this diagnosis —the constant struggle with a visible condition that affects how you may feel about yourself. At IgGenix, we’re working hard to change that.